Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903374 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL13191563 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL14967631 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL23026252 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL4077048 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL24149222 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL903332 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL21312802 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL21312685 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA | |
| SCHEMBL15161122 | 1.00 | LGALS3 (0.34) | LGALS3THRBLMNAOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560231-B2 | Mannitol and glucitol derivatives | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1431298-B1 | Mannitol and glucitol derivatives | ROCHE DIAGNOSTICS GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040157247-A1 | Mannitol and glucitol derivatives | ROCHE MOLECULAR SYSTEMS, INC (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1431298-A1 | Mannitol and glucitol derivatives | Roche Diagnostics GmbH (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1431297-A1 | Mannitol and glucitol derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157247-A1 | Mannitol and glucitol derivatives | ALDOA, DERA, SORD | LGALS3 163/4885THRB 4177/4885LMNA 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.